ProShare Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

ProShare Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-8,522	Closed	-$409K	–	1700
2020 Q1	$409K	Sell	8,522 -6,391	-43%	-$297K	﹤0.01%	781
2019 Q4	$700K	Sell	14,913 -1,779	-11%	-$78.6K	﹤0.01%	929
2019 Q3	$395K	Buy	16,692 +2,352	+16%	+$69.7K	﹤0.01%	1082
2019 Q2	$431K	Sell	14,340 -1,988	-12%	-$45.5K	﹤0.01%	1075
2019 Q1	$366K	Buy	16,328 +3,810	+30%	+$81.9K	﹤0.01%	1161
2018 Q4	$228K	Sell	12,518 -2,438	-16%	-$38.3K	﹤0.01%	1302
2018 Q3	$271K	Sell	14,956 -516	-3%	-$6.12K	﹤0.01%	1422
2018 Q2	$154K	Sell	15,472 -938	-6%	-$6.48K	﹤0.01%	1667
2018 Q1	$87K	Buy	16,410 +2,475	+18%	+$17.7K	﹤0.01%	1648
2017 Q4	$118K	Buy	+13,935	New	+$171K	﹤0.01%	1722

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

ProShare Advisors's RARX Position: Q2 2020 in Review

ProShare Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 8,522 shares — an estimated $409K sold.

ProShare Advisors first reported a position in RARX in Q4 2017 and held it in 10 quarters. The position peaked at $700K in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

ProShare Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
ProShare Advisors sold 8,522 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $409K.
ProShare Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 10 quarters.
ProShare Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $700K in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on ProShare Advisors's 13F filing for Q2 2020, filed 3 Aug 2020.